US FDA extends review of Exelixis’ cancer drug
Sept 11 (Reuters) – The U.S. Food and Drug Administration has extended the review of Exelixis’ experimental colorectal cancer drug combination by three months, the company said in a filing on Friday. The regulator will now make its decision by March 3, 2027. Shares of the company slipped about 3.5%


























